Health-related quality of life after transient ischemic attack and minor stroke: is medical or surgical treatment influential?

Although randomized trials have proven the benefit of carotid endarterectomy (CEA) for appropriate patients, health care purchasers increasingly look beyond clinical outcome toward measures of cost effectiveness and health-related quality of life (HRQoL) in apportioning limited resources. We used a generic HRQoL outcome scale, the Short Form 36 (SF-36), to assess the differences in patient-perceived HRQoL in two cohorts of patients who had suffered minor cerebral ischemic events. One group (n=100) had undergone CEA, whereas members of the second cohort (n=100) were not appropriate candidates for surgery and were therefore treated with best medical therapy. The overall response rate was 83%. No significant difference in health profile between the CEA and medical cohorts was detected for the eight SF-36 domains. However, the CEA cohort rated a significantly improved change in general health over the previous year compared with the group managed medically (P<.01). A greater proportion of the former group than of the medical group thought their treatment had been successful and that their health had been improved by treatment (P<.01). Both groups shared the same anxieties over future cerebral ischemic events (P=.3). Patients' perception of HRQoL measured by the SF-36 domains was almost identical between the CEA and medical cohorts apart from a small but significant improvement in self-reported overall health in the CEA cohort. HRQoL outcome measures may be of value in future clinical trials of cerebral revascularization.